AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29692272 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive self-image
Number of subjects: 42
Study 29692272 — intervention group
Group type: COMPARATOR
Intervention: Negative self-image
Number of subjects: 42
Study 29773490 — intervention group
Group type: EXPERIMENTAL
Intervention: VSM arm (study website with vaccine information and social media components)
Number of subjects: 1093
Study 29773490 — intervention group
Group type: EXPERIMENTAL
Intervention: VI arm (website with vaccine information only)
Number of subjects: 1093
Study 29773490 — intervention group
Group type: COMPARATOR
Intervention: VSM arm
Number of subjects: 1093
Study 29773490 — intervention group
Group type: COMPARATOR
Intervention: VI arm
Number of subjects: 1093
Study 29773490 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy around vaccine decision making
Number of subjects: 1093
Study 29773490 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1093
Study 26708921 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for ESD-induced perforation
Number of subjects: 2046
Study 26708921 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified weighted scoring system based on OR
Number of subjects: 2046
Study 24415868 — intervention group
Group type: EXPERIMENTAL
Intervention: CIGB-230
Number of subjects: 0
Study 24415868 — intervention group
Group type: EXPERIMENTAL
Intervention: CIGB-230 (6 doses as late add-on)
Number of subjects: 0
Study 24415868 — intervention group
Group type: COMPARATOR
Intervention: Control (no CIGB-230)
Number of subjects: 0
Study 23111478 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy for 6 months
Number of subjects: 391
Study 23111478 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 391
Study 21029466 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous computer analysis of fetal monitoring signals with real-time alerts
Number of subjects: 8133
Study 21029466 — intervention group
Group type: COMPARATOR
Intervention: Continuous CTG monitoring as previously performed
Number of subjects: 8133
Study 18403419 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible GnRH antagonist protocol
Number of subjects: 270
Study 18403419 — intervention group
Group type: COMPARATOR
Intervention: Flare-up GnRH agonist protocol
Number of subjects: 270
Study 15816587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 209
Study 15816587 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 209
Study 15816587 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural vein cannulation
Number of subjects: 209
Study 12459133 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (verbal and written information on generic vs brand-name drugs)
Number of subjects: 4620
Study 12459133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 4620
Study 12459133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (after intervention, before reference prices)
Number of subjects: 4620
Study 12459133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (after application of reference prices)
Number of subjects: 4620
Study 12459133 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 4620
Study 12459133 — intervention group
Group type: COMPARATOR
Intervention: Control practices (after intervention, before reference prices)
Number of subjects: 4620
Study 12459133 — intervention group
Group type: COMPARATOR
Intervention: Control practices (after application of reference prices)
Number of subjects: 4620
Study 10385781 — intervention group
Group type: EXPERIMENTAL
Intervention: Second harmonic imaging
Number of subjects: 40
Study 10385781 — intervention group
Group type: COMPARATOR
Intervention: Fundamental imaging
Number of subjects: 40
Study 8583018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse, 18 mg per rinse
Number of subjects: 24
Study 8583018 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse, 20 mg per rinse
Number of subjects: 24
Study 8583018 — intervention group
Group type: COMPARATOR
Intervention: Control rinse (not specified)
Number of subjects: 24
Study 2127178 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamid‐ratiopharm (treatment A)
Number of subjects: 80
Study 2127178 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (treatment B)
Number of subjects: 80
Study 6117901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prostacyclin (PGI2) and heparin
Number of subjects: 24
Study 6117901 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 24
Study 30870257 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopiclenol (0.025, 0.05, 0.075, 0.1, 0.2, and 0.3 mmol/kg)
Number of subjects: 66
Study 30870257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 66
Study 30870257 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopiclenol (0.05, 0.075, 0.1, and 0.2 mmol/kg)
Number of subjects: 66
Study 26023778 — intervention group
Group type: EXPERIMENTAL
Intervention: Two dose booster regimen of OCV (n = 184)
Number of subjects: 426
Study 26023778 — intervention group
Group type: EXPERIMENTAL
Intervention: Single boosting dose of OCV
Number of subjects: 426
Study 26023778 — intervention group
Group type: COMPARATOR
Intervention: Two dose primary series of OCV (n = 186)
Number of subjects: 426
Study 26023778 — intervention group
Group type: COMPARATOR
Intervention: Primary regimen in children
Number of subjects: 426
Study 26023778 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosting regimen in children
Number of subjects: 426
Study 24224448 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee with caffeine
Number of subjects: 17
Study 24224448 — intervention group
Group type: COMPARATOR
Intervention: Instant coffee without caffeine
Number of subjects: 17
Study 24224448 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural coffee with caffeine
Number of subjects: 17
Study 24224448 — intervention group
Group type: COMPARATOR
Intervention: Natural coffee without caffeine
Number of subjects: 17
Study 21640866 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) solution
Number of subjects: 20
Study 21640866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remineralization)
Number of subjects: 20
Study 19540392 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony-stimulating factor (GM-CSF) 3, 6, or 10 microg/kg per day
Number of subjects: 45
Study 19540392 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 45
Study 19540392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16708532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg slow release)
Number of subjects: 8
Study 16708532 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 8
Study 16708532 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (6-hour prophylactic sleep)
Number of subjects: 8
Study 15270791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 6117
Study 15270791 — intervention group
Group type: COMPARATOR
Intervention: Danish risk score
Number of subjects: 6117
Study 15270791 — intervention group
Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 6117
Study 15270791 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted screening using questionnaire followed by FPG
Number of subjects: 6117
Study 15270791 — intervention group
Group type: COMPARATOR
Intervention: Population-based screening using FPG
Number of subjects: 6117
Study 15270791 — intervention group
Group type: COMPARATOR
Intervention: Combination of questionnaire and FPG
Number of subjects: 6117
Study 11453515 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential training
Number of subjects: 50
Study 11453515 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational training
Number of subjects: 50
Study 11453515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 9550641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg o.d. (slow release formulation) for 1 week
Number of subjects: 10
Study 9550641 — intervention group
Group type: COMPARATOR
Intervention: Control measurements (no specific intervention mentioned)
Number of subjects: 10
Study 8054323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar beet (SB) fibre
Number of subjects: 6
Study 8054323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula (I) fibre
Number of subjects: 6
Study 8054323 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran (WB) fibre
Number of subjects: 6
Study 8054323 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 6
Study 2903386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole for 5 days
Number of subjects: 134
Study 2903386 — intervention group
Group type: COMPARATOR
Intervention: Single intramuscular dose of fortified procaine penicillin and 5 days of oral ampicillin
Number of subjects: 134
Study 7992070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 224
Study 384325 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 51
Study 384325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30291011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic BP<120mmHg)
Number of subjects: 529
Study 30291011 — intervention group
Group type: COMPARATOR
Intervention: Less intensive blood pressure target (systolic BP<140mmHg)
Number of subjects: 529
Study 28276086 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-but not Alone mobile health application educational programme
Number of subjects: 250
Study 28276086 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 250
Study 27638058 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) with inspiratory resistance device set to 55% of maximum inspiratory effort (n=35)
Number of subjects: 67
Study 27638058 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with inspiratory resistance device set to 10% of maximum inspiratory effort (n=32)
Number of subjects: 67
Study 24375223 — intervention group
Group type: COMPARATOR
Intervention: Low thoracic-epidural analgesia (TEA)
Number of subjects: 44
Study 24375223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus-abdominis plane (TAP) block
Number of subjects: 44
Study 22959906 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 165
Study 22959906 — intervention group
Group type: COMPARATOR
Intervention: MPA
Number of subjects: 165
Study 19572180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser at 585 nm
Number of subjects: 15
Study 19572180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser at 595 nm
Number of subjects: 15
Study 19572180 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 15
Study 19572180 — intervention group
Group type: COMPARATOR
Intervention: All groups (585 nm, 595 nm, and control)
Number of subjects: 15
Study 19572180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 585 nm and 595 nm PDL treatments
Number of subjects: 15
Study 17895284 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone only
Number of subjects: 52
Study 17895284 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol only
Number of subjects: 52
Study 17895284 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and estradiol
Number of subjects: 52
Study 17895284 — intervention group
Group type: EXPERIMENTAL
Intervention: No testosterone and no estradiol
Number of subjects: 52
Study 14535874 — intervention group
Group type: EXPERIMENTAL
Intervention: LC1 (fermented milk containing Lactobacillus johnsonii)
Number of subjects: 50
Study 10895201 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m2 IV bolus) followed one hour later by Taxotere (60 mg/m2 IV infusion over 1 hour every 3 weeks for 6 cycles)
Number of subjects: 18
Study 8831596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 123
Study 8831596 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefotaxime
Number of subjects: 123
Study 1578593 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine, 8 mg/d
Number of subjects: 162
Study 1578593 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone, 60 mg/d
Number of subjects: 162
Study 1578593 — intervention group
Group type: COMPARATOR
Intervention: Methadone, 20 mg/d
Number of subjects: 162
Study 3841130 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate with a high fat meal
Number of subjects: 8
Study 3841130 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate with whole milk
Number of subjects: 8
Study 3841130 — intervention group
Group type: COMPARATOR
Intervention: Etretinate with a high carbohydrate meal
Number of subjects: 8
Study 3841130 — intervention group
Group type: COMPARATOR
Intervention: Etretinate during a complete fast
Number of subjects: 8
Study 30916161 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 52
Study 30916161 — intervention group
Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 52
Study 28451529 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened self-management program guidance (including seven modules: disease knowledge, breathing exercises, emotion management, home oxygen therapy, medicine intake technique, healthy life behaviors, action plans in deterioration stage)
Number of subjects: 86
Study 28451529 — intervention group
Group type: COMPARATOR
Intervention: Conventional out-of-hospital continued nursing mode
Number of subjects: 86
Study 28451529 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened self-management program guidance
Number of subjects: 86
Study 25946480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage (CS) transfusion
Number of subjects: 91
Study 25946480 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed stored erythrocyte transfusion
Number of subjects: 91
Study 25946480 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwashed stored erythrocyte transfusion
Number of subjects: 91
Study 23046735 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered taste perception
Number of subjects: 1745
Study 21074809 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaris ureteral stent
Number of subjects: 159
Study 21074809 — intervention group
Group type: COMPARATOR
Intervention: InLay ureteral stent
Number of subjects: 159
Study 19554005 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for inducible myocardial ischemia
Number of subjects: 0
Study 19554005 — intervention group
Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 0
Study 17242627 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 or 6 mg depending on body weight)
Number of subjects: 105
Study 17242627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15473343 — intervention group
Group type: EXPERIMENTAL
Intervention: Blink Reflex (BR) elicited by stimulation of the supraorbital nerve
Number of subjects: 67
Study 15473343 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 67
Study 11736864 — intervention group
Group type: EXPERIMENTAL
Intervention: Six drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, chlorzoxazone 250 mg, diclofenac 25 mg, MDZ 5 mg)
Number of subjects: 16
Study 11736864 — intervention group
Group type: COMPARATOR
Intervention: MDZ alone
Number of subjects: 16
Study 11736864 — intervention group
Group type: EXPERIMENTAL
Intervention: Five drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, diclofenac 50 mg, without chlorzoxazone)
Number of subjects: 16
Study 11736864 — intervention group
Group type: EXPERIMENTAL
Intervention: Six drug cocktail (as above with chlorzoxazone)
Number of subjects: 16
Study 9431858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (2 mg once daily)
Number of subjects: 19
Study 9431858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg once daily)
Number of subjects: 19
Study 9431858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine plus Hydrochlorothiazide
Number of subjects: 19
Study 9431858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8305770 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylan's MTX tablets (15 mg administered as six 2.5-mg tablets)
Number of subjects: 22
Study 8305770 — intervention group
Group type: COMPARATOR
Intervention: Lederle's MTX tablets (15 mg administered as six 2.5-mg tablets)
Number of subjects: 22
Study 8305770 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Mylan's MTX to Lederle's MTX
Number of subjects: 22
Study 3790405 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 5
Study 3790405 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 5
Study 3790405 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study 3790405 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs (Atropine and Glycopyrrolate)
Number of subjects: 5
Study 31574025 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosclerotherapy (EST)
Number of subjects: 5
Study 31574025 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin injection
Number of subjects: 5
Study 31574025 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 5
Study 30415082 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention including reminders, care algorithms, training of a case manager, audit and feedback reports, and distribution of educational materials to health care providers.
Number of subjects: 0
Study 30415082 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (control)
Number of subjects: 0
Study 28733374 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c measurement
Number of subjects: 387
Study 28733374 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 387
Study 28733374 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated HbA1c (eA1C) calculation
Number of subjects: 387
Study 25441015 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with memory reactivation (n=10)
Number of subjects: 76
Study 25441015 — intervention group
Group type: COMPARATOR
Intervention: Propranolol without memory reactivation (n=8)
Number of subjects: 76
Study 25441015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone with memory reactivation (n=13)
Number of subjects: 76
Study 25441015 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone without reactivation (n=15)
Number of subjects: 76
Study 25441015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone plus d-cycloserine with reactivation (n=16)
Number of subjects: 76
Study 25441015 — intervention group
Group type: COMPARATOR
Intervention: Two placebos (n=15)
Number of subjects: 76
Study 23530962 — intervention group
Group type: EXPERIMENTAL
Intervention: Full mouth periodontal treatment with an ultrasonic device and supragingival plaque control
Number of subjects: 15
Study 21784145 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 supplementation (2.5 g/d, 2085 mg eicosapentaenoic acid and 348 mg docosahexanoic acid)
Number of subjects: 68
Study 19322003 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin (group 1, 34 patients)
Number of subjects: 107
Study 19322003 — intervention group
Group type: EXPERIMENTAL
Intervention: terazosin (group 2, 35 patients)
Number of subjects: 107
Study 19322003 — intervention group
Group type: COMPARATOR
Intervention: placebo (group 3, 38 patients)
Number of subjects: 107
Study 19322003 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin (group 1)
Number of subjects: 107
Study 19322003 — intervention group
Group type: EXPERIMENTAL
Intervention: terazosin (group 2)
Number of subjects: 107
Study 19322003 — intervention group
Group type: COMPARATOR
Intervention: placebo (group 3)
Number of subjects: 107
Study 16751617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic-hyperoncotic solution (Poly-(O-2)-hydroxyethyl-starch 60.0 g, Na+ 1232 mmol/L, osmolality 2464 mOsmol/L)
Number of subjects: 50
Study 16751617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic-hyperoncotic solution
Number of subjects: 50
Study 16751617 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution (0.9% sodium chloride)
Number of subjects: 50
Study 16751617 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 50
Study 15310688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse based outpatient management programme
Number of subjects: 208
Study 15310688 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow up
Number of subjects: 208
Study 11220717 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole therapy (40 or 60 mg daily as needed)
Number of subjects: 310
Study 11220717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 310
Study 9627297 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal macrophages of women with endometriosis
Number of subjects: 31
Study 9627297 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophages of women with endometriosis
Number of subjects: 31
Study 9627297 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid (PF) of women with endometriosis
Number of subjects: 31
Study 9627297 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot analysis
Number of subjects: 31
Study 7931474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A (100,000 IU/d) for 18 months
Number of subjects: 248
Study 7931474 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 248
Study 3229297 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg L-acetylcarnitine
Number of subjects: 10
Study 3229297 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg L-acetylcarnitine
Number of subjects: 10